Unravelling the enigma of siRNA and aptamer mediated therapies against pancreatic cancer
Abstract Pancreatic cancer (PC) is a fatal disease that has a poor 5-year survival rate. The poor prognosis can be attributed to both troublesome detections at the initial stage, which makes the majority of the treatment options largely unsuccessful and leads to extensive metastasis, as well as to i...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-01-01
|
| Series: | Molecular Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12943-022-01696-5 |
| _version_ | 1797952626274336768 |
|---|---|
| author | Zhe Liu Neha Parveen Urushi Rehman Aisha Aziz Afsana Sheikh Mohammed A. S. Abourehab Wei Guo Junhao Huang Zhenning Wang Prashant Kesharwani |
| author_facet | Zhe Liu Neha Parveen Urushi Rehman Aisha Aziz Afsana Sheikh Mohammed A. S. Abourehab Wei Guo Junhao Huang Zhenning Wang Prashant Kesharwani |
| author_sort | Zhe Liu |
| collection | DOAJ |
| description | Abstract Pancreatic cancer (PC) is a fatal disease that has a poor 5-year survival rate. The poor prognosis can be attributed to both troublesome detections at the initial stage, which makes the majority of the treatment options largely unsuccessful and leads to extensive metastasis, as well as to its distinct pathophysiological characteristics, such as rich desmoplastic tumours bounded by dysplastic and hypo perfused vessels restricting the mobility of therapeutic agents. Continued attempts have been made to utilise innovative measures for battling PC to increase the therapeutic effectiveness of therapies and overcome their cytotoxicity. Combined cancer targeting and gene silencing approach has shown improved outcomes in patients’ survival rates and quality of life, offering a potential solution to therapeutic complications. It particularly targets various barriers to alleviate delivery problems and diminish tumour recurrence and metastasis. While aptamers, a type of single-stranded nucleic acids with strong binding affinity and specificity to target molecules, have recently surfaced as a viable PC strategy, siRNA can interfere with the expression of certain genes. By concurrently suppressing genes and boosting targeted approach, the cocktail of siRNA/Aptamer and other therapeutic drugs can circumvent the multi-drug resistance phenomena. Additionally, combination therapy with additive or synergistic effects can considerably increase the therapeutic efficacy of anti-cancer medications. This study outlines the primary difficulties in treating PC, along with recent developments in siRNA/Aptamer mediated drug delivery to solve the major hiccup of oncology field. Graphical Abstract |
| first_indexed | 2024-04-10T22:50:25Z |
| format | Article |
| id | doaj.art-6c42eaf85cd0408a8940a4f4b063bac1 |
| institution | Directory Open Access Journal |
| issn | 1476-4598 |
| language | English |
| last_indexed | 2024-04-10T22:50:25Z |
| publishDate | 2023-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Molecular Cancer |
| spelling | doaj.art-6c42eaf85cd0408a8940a4f4b063bac12023-01-15T12:05:55ZengBMCMolecular Cancer1476-45982023-01-0122112210.1186/s12943-022-01696-5Unravelling the enigma of siRNA and aptamer mediated therapies against pancreatic cancerZhe Liu0Neha Parveen1Urushi Rehman2Aisha Aziz3Afsana Sheikh4Mohammed A. S. Abourehab5Wei Guo6Junhao Huang7Zhenning Wang8Prashant Kesharwani9Department of Pancreatic-Biliary Surgery, The First Hospital of China Medical UniversityDepartment of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia HamdardDepartment of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia HamdardDepartment of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia HamdardDepartment of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia HamdardDepartment of Pharmaceutics, College of Pharmacy, Umm Al-Qura UniversityDepartment of Pancreatic-Biliary Surgery, The First Hospital of China Medical UniversityDepartment of Pancreatic-Biliary Surgery, The First Hospital of China Medical UniversityDepartment of Surgical Oncology and General Surgery, The First Hospital of China Medical UniversityDepartment of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia HamdardAbstract Pancreatic cancer (PC) is a fatal disease that has a poor 5-year survival rate. The poor prognosis can be attributed to both troublesome detections at the initial stage, which makes the majority of the treatment options largely unsuccessful and leads to extensive metastasis, as well as to its distinct pathophysiological characteristics, such as rich desmoplastic tumours bounded by dysplastic and hypo perfused vessels restricting the mobility of therapeutic agents. Continued attempts have been made to utilise innovative measures for battling PC to increase the therapeutic effectiveness of therapies and overcome their cytotoxicity. Combined cancer targeting and gene silencing approach has shown improved outcomes in patients’ survival rates and quality of life, offering a potential solution to therapeutic complications. It particularly targets various barriers to alleviate delivery problems and diminish tumour recurrence and metastasis. While aptamers, a type of single-stranded nucleic acids with strong binding affinity and specificity to target molecules, have recently surfaced as a viable PC strategy, siRNA can interfere with the expression of certain genes. By concurrently suppressing genes and boosting targeted approach, the cocktail of siRNA/Aptamer and other therapeutic drugs can circumvent the multi-drug resistance phenomena. Additionally, combination therapy with additive or synergistic effects can considerably increase the therapeutic efficacy of anti-cancer medications. This study outlines the primary difficulties in treating PC, along with recent developments in siRNA/Aptamer mediated drug delivery to solve the major hiccup of oncology field. Graphical Abstracthttps://doi.org/10.1186/s12943-022-01696-5siRNAAptamersNanoparticlesCombination therapyChemotherapeuticPancreatic cancer |
| spellingShingle | Zhe Liu Neha Parveen Urushi Rehman Aisha Aziz Afsana Sheikh Mohammed A. S. Abourehab Wei Guo Junhao Huang Zhenning Wang Prashant Kesharwani Unravelling the enigma of siRNA and aptamer mediated therapies against pancreatic cancer Molecular Cancer siRNA Aptamers Nanoparticles Combination therapy Chemotherapeutic Pancreatic cancer |
| title | Unravelling the enigma of siRNA and aptamer mediated therapies against pancreatic cancer |
| title_full | Unravelling the enigma of siRNA and aptamer mediated therapies against pancreatic cancer |
| title_fullStr | Unravelling the enigma of siRNA and aptamer mediated therapies against pancreatic cancer |
| title_full_unstemmed | Unravelling the enigma of siRNA and aptamer mediated therapies against pancreatic cancer |
| title_short | Unravelling the enigma of siRNA and aptamer mediated therapies against pancreatic cancer |
| title_sort | unravelling the enigma of sirna and aptamer mediated therapies against pancreatic cancer |
| topic | siRNA Aptamers Nanoparticles Combination therapy Chemotherapeutic Pancreatic cancer |
| url | https://doi.org/10.1186/s12943-022-01696-5 |
| work_keys_str_mv | AT zheliu unravellingtheenigmaofsirnaandaptamermediatedtherapiesagainstpancreaticcancer AT nehaparveen unravellingtheenigmaofsirnaandaptamermediatedtherapiesagainstpancreaticcancer AT urushirehman unravellingtheenigmaofsirnaandaptamermediatedtherapiesagainstpancreaticcancer AT aishaaziz unravellingtheenigmaofsirnaandaptamermediatedtherapiesagainstpancreaticcancer AT afsanasheikh unravellingtheenigmaofsirnaandaptamermediatedtherapiesagainstpancreaticcancer AT mohammedasabourehab unravellingtheenigmaofsirnaandaptamermediatedtherapiesagainstpancreaticcancer AT weiguo unravellingtheenigmaofsirnaandaptamermediatedtherapiesagainstpancreaticcancer AT junhaohuang unravellingtheenigmaofsirnaandaptamermediatedtherapiesagainstpancreaticcancer AT zhenningwang unravellingtheenigmaofsirnaandaptamermediatedtherapiesagainstpancreaticcancer AT prashantkesharwani unravellingtheenigmaofsirnaandaptamermediatedtherapiesagainstpancreaticcancer |